What happens at Wegovy month 3?

What dose are most people on by week 12?

Wegovy follows a structured escalation: 0.25 mg to start, moving through 0.5 mg, 1.0 mg, 1.7 mg and eventually 2.4 mg, each step held for roughly four weeks. Twelve weeks in, the majority of people are either finishing their time at 1.0 mg or moving up to 1.7 mg. A smaller group, those who needed an extra week or two at a lower level to manage side effects, may still be at 1.0 mg. Neither position is a problem; the schedule is a guide, not a deadline.

What changes at this stage is that appetite suppression tends to feel more consistent. Early on, the effect can fluctuate within the week, strongest in the day or two after injection and fading slightly by day six or seven. By month three, many people report the hunger reduction feeling steadier. That is partly familiarity, partly the dose being higher, and partly individual pharmacology. The Wegovy treatment overview explains the licensed schedule in more detail if you want the full picture.

One practical thing worth knowing: dose-increase timing is sometimes disrupted by life rather than medicine. A bank holiday, a holiday abroad, or ordering on the last Friday before a long weekend can push an injection back. If that happens to you, your prescriber and the Patient Information Leaflet are the right guides for what to do, not guesswork.

How much weight loss is typical in the first three months?

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks and found an average total weight reduction of around 15% at the 2.4 mg maintenance dose. At week 12, trial participants were still on their way up the titration ladder, so average loss at that point was meaningfully lower than the eventual figure. Real-world data suggests many people see somewhere between 5% and 10% of their starting weight gone by month three, though the range is wide.

Slower progress in months one and two is common and does not predict a poor eventual response. Titration, digestive adjustment, and simply finding the dietary rhythm that works alongside reduced appetite all take time. The three-month weight loss guide goes deeper on what the evidence says about outcomes at this specific milestone. For a granular look at what month four typically brings as doses climb further, the month four page covers that next phase.

What the trial cannot tell you is whether your body will respond closer to the average or at either end of the distribution. A prescriber reviewing your actual progress, ideally with your weight and health data in front of them, is a more useful guide than any population statistic.

Do side effects get better by month three?

For most people, yes. The GI symptoms that arrive with each dose increase, most often nausea, loose stools, or a full feeling after small meals, tend to be sharpest in the first few days after stepping up and then settle. By month three, people who started with significant nausea at lower doses frequently report that it has largely resolved. That pattern tracks with how semaglutide works: the gut adjusts to slowed gastric emptying over time.

The caveat is that each new dose increase can bring a shorter, milder replay of early side effects. Moving from 1.0 mg to 1.7 mg may bring a week of renewed nausea even if 1.0 mg had become completely comfortable. This is normal and expected. The semaglutide information page covers the full side-effect profile in plain language, and the NHS semaglutide medicines page lists what to watch for and when to seek help.

The signs that do warrant prompt medical attention at any stage of treatment include severe, persistent stomach pain that radiates to the back (a possible indicator of pancreatitis), symptoms of a serious allergic reaction, or significant dehydration from prolonged vomiting or diarrhoea. If you experience any of those, contact a clinician the same day rather than waiting for your next scheduled review. Side effects can also be reported to the MHRA via the Yellow Card scheme.

Is month three when you should think about what comes next?

It is a reasonable time to take stock. NICE's guidance on semaglutide for weight management (TA875) includes a review at six months on maintenance dose: if weight loss is less than 5% by that point, continuing is reviewed. Month three is well before that formal threshold, but it is the stage where patterns start becoming readable. Are you finding meals smaller? Is energy improving? Are you hitting the ceiling of what your current dose is doing?

Those are questions for a prescriber, not a self-assessment checklist. At nume, a GPhC-registered prescriber looks at your responses before every repeat order, not just at the start. No auto-renewal, no prescription issued on autopilot. If you are weighing up how the private route compares to NHS waiting times and criteria, the weight loss treatment overview sets out both options clearly. Curious about what month two looked like for comparison? The first month guide and the month two page fill in the earlier picture. For a transparent look at private prescription costs, the Wegovy cost guide explains what legitimate pricing actually covers.

If you are considering starting, or want your current progress reviewed by a clinician, check your eligibility with our prescribers. It's a free consultation, reviewed the same day.